antibiotics

IMPACT FACTOR 4.3

Indexed in: PubMed

CITESCORE 7.3

an Open Access Journal by MDPI

Antibiotic Resistance and Treatment of MRSA Infection

Guest Editor:

Dr. Jae-Seok Kim
Department of Laboratory Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea

Deadline for manuscript submissions:
closed (15 March 2021)

Message from the Guest Editor

Staphylococcus aureus is a major human pathogen associated with hospital-acquired infections, as well as an emerging cause of community-acquired infections. The selective pressure exerted by the appropriate and/or inappropriate use of antibiotics to treat S. aureus infections results in diverse resistance genes that lead to the development of antimicrobial resistance. Moreover, S. aureus capacity to form biofilms, to antimicrobial resistance and makes treatment more challenging.

This Issue thus aims to provide various strategies to treat MRSA infections. Moreover, studies aiming at elucidating the molecular basis of antimicrobial resistance, target identification, and drug development are also welcome. The overall aim is to bring together the most up-to-date perspectives and research in the areas of:

1. Development of novel drugs, vaccines, and preventive strategies against MRSA infection;
2. Adjuvant to antibiotics/combination therapy;
3. Molecular determinant of antimicrobial resistance;
4. Successes and challenges for MRSA infection control.

Keywords: MRSA ; antimicrobial resistance ; *mecA* ; PBP ; β-lactamase ; biofilm formation ; drug discovery

antibiotics

IMPACT FACTOR 4.3 | Indexed in: PubMed | CITESCORE 7.3

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
𝕏@antibioticsmdpi